PCSK9 and neoplasm: Lowering cholesterol levels through genetic or pharmacological inhibition of PCSK9 suppresses MDSC expansion, pro-tumoral TAM accumulation, and tumor progression in a RORγ-dependent manner, thereby unleashing specific anti-tumor immunity [163].